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Abstract
According to surveys and opinion polls, citizens in Nordic welfare societies have positive,
supportive attitudes towards medical research and biobanking. In Finland, it was
expected that this would result in the active biobank participation of patients
and citizens. Indeed, public support has been rhetorically utilised as a unique
societal factor and advantage in the promotion of Finnish biobanks, underlining
the potential Finland offers for the international biomedical enterprise. In this
paper, we critically analyse the use of notions such as ‘willing population’ and
‘engaged people’ in the promotion and legitimation of biobanking. First, there is
a seeming contradiction between positive attitudes and actual participation rates,
as biobanks have faced unexpected challenges in participant recruitment during
the first years of their operations. As a result, the concept of a willing population was
redirected to problematise the necessity of informed consent. Second, we question
whether it is even meaningful to assume the existence of an informed and engaged
population with regard to biobanking. Therefore, we suggest that it is problematic to
talk about a willing population at the same time as the relevance of the informed
consent system is being questioned by biobank actors and policy makers. We analyse
this tension in relation to existing data on Finnish people’s attitudes, pointing out that
positive, supportive views do not directly transform into high participation rates; nor do
they justify the claims of policy makers and biobank proponents that people are willing
to participate, when in fact surveys report that people know very little about biobanks.
Keywords: Biobanks, Participation, Innovation policy, Finland, Informed consent,
Public opinion
Introduction
Biobank activities in Finland are governed by the Biobank Act of 2013; since then ten
biobanks have been established with high hopes that they will collect thousands of new
prospective samples, ‘capturing all incomers’ (see Tupasela et al. 2015). Of these ten
biobanks, nine are publicly funded: biobank of the National Institute of Health and
Welfare, six clinical biobanks of hospital districts, a disease-specific biobank and the
biobank of the Finnish Blood Service. The only private biobank, which is owned by a
health care company, started its operations in 2018. In general, biobanks can be
defined as social and technical arrangements for the collection, storage and distribu-
tion of tissue samples or other biological material and the medical and lifestyle data
related to them. Due to advancements in genomics and in the technological capacity
to work with larger data-sets, biobanks and transnational biobank networks are widely
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considered essential infrastructure for contemporary biomedical research, and vital
elements of the knowledge-based bioeconomy (e.g., Yuille et al. 2007, Gottweis and
Petersen 2008, Leonelli 2016). Currently, biobanks are not only part of the biomedical
research structure but part of the landscape of new, large-scale, health data networks
and ecosystems. Yet favourable public response and the willingness of individuals to
donate samples and personal information are prerequisites for the collection and distri-
bution of the bioinformation in biobanks (e.g. Levitt 2011, Levitt and Weldon 2005),
and thus the enablers of economic development (Tarkkala et al. 2018, Hoeyer 2016).
Finland is known for high levels of trust in society (Gaskell et al. 2013, Väliverronen
2007), and Finns have also been reported to have higher levels of trust in public institu-
tions and authorities, experts, scientific research and medical doctors than Europeans
on average (Tupasela and Snell 2012, Eurobarometer 2010, Gaskell and Gottweis 2011,
Snell et al. 2012). The opinions of Finns and the inhabitants of the other Nordic
Welfare states – Sweden, Norway, Iceland and Denmark – are also among the most
positive in Europe in regard to the possibilities of science and technology, medical
research and biobanks (Eurobarometer 2010, 2014). These positive attitudes are often
linked to the long history of the welfare state and its extensive public population and
health registers, and comprehensive tissue collections, which have been utilized in
research for decades (Tarkkala et al. 2018, Tupasela et al. 2015). Biobanks in Finland
are for the most part associated institutionally and financially to the public sector and
are framed as continuing this tradition of collecting samples and data. Therefore, refer-
ences to ‘trust’, ‘willingness’ and ‘the positive attitudes of the population’, when it comes
to research participation, can be considered an established narrative (Prainsack 2007)
in Finland that contributes to the legitimation of science, medicine, technology and,
concomitantly, biobanks. As Prainsack (2007) has further observed, when the rhetoric
employed by biobank promotors corresponds with established narratives, this increases
the likelihood of obtaining public support and trust.
Public support has been mentioned in health sector innovation strategies and visions as
an important competitive advantage for Finland; the population has often been described as
‘willing’ to participate, which is seen as a critical factor in the potential success of Finnish
biobanks (see, e.g., Ministry of Social Affairs and Health 2015, 20, Ministry of Social Affairs
and Health 2016). Furthermore, labels of ‘willing’ or ‘engaged’ prevent associations with ex-
ploitation (e.g., Vora 2015). Consequently, this kind of reasoning – the significance of a will-
ing and educated population in creating a success story of biomedical research – was used
in Iceland about 20 years ago when Decode Genetics and IHDB were founded (see, e.g.,
Rose 2003, Tarkkala 2019). Yet many countries are also branded as ‘the place to be’ for bio-
medical or clinical studies based on a population that is presented as having an exception-
ally useful genetic or social background in terms of uniqueness or diversity (see Tupasela
2017, Benjamin 2009, Ong 2016, Tarkkala and Tupasela 2018). Finland likewise exemplifies
a country rhetorically framed as offering a competitive population for international biomed-
ical research, in Finland’s case due to its biological homogeneity, but in this study we focus
on a social characteristic that is deployed to advantage: the ‘willingness’ and supportive atti-
tudes of its population (see also Rose 2003). Similar taken-for-granted assumptions about
populations, right ways to organise biobanking or participation, and their implications can
be observed in other national and multinational initiatives and in science and technology
policy (Busby 2006, Woolley et al. 2016, Welsh and Wynne 2013).
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When the first biobanks were founded in Finland in 2013–2015, it was expected that
the positive attitudes of the country’s citizens towards research would result in their
active participation. This did not materialise, however, and many biobanks struggled to
attract donors. The recruitment process, and the informed consent system supporting
it, were therefore identified as impeding the success of Finnish biobanks (Ministry of
Social Affairs and Health 2016). Nevertheless, this recognition did not result in the
abandonment or even problematisation of the rhetoric of a willing population. Instead,
as we argue in this article, alongside its continued deployment in highlighting Finland’s
competitiveness, the notion of a ‘willing population’ was re-harnessed to support the
abandonment of informed consent. The argument goes that, as the majority of Finns
are positive about biobanks, there should be no need to obtain formal consent (Minis-
try of Social Affairs and Health 2016); the required accumulation of samples and data
could be secured by referring to the public good as a legislative base for collection. This
turn towards abandonment of informed consent was a move to amend biobank legisla-
tion, which started almost immediately after the first law came into force and provided
a facilitating environment. Further reasoning supporting the initiative related to the his-
tory of Finland as a Nordic welfare state and the long tradition of gathering register
data. Biobank samples and data were presented as similar to, and therefore a continu-
ation of, this tradition, which had not required consent in the past, making biobanking
just business as usual.
We start from the contradiction between expectations of population enrolment in
biobanks and actual participation rates. Moving on from there, we question the utilisa-
tion of notions such as ‘willing population’ and ‘engaged people’ to legitimise biobank-
ing and biomedical research, claiming that such labels are neither empirically nor
ethically defensible given that a large proportion of Finns do not know what a biobank
is (Snell 2017). The public support for science and trust in medical experts identified in
surveys do not equate with informed willingness to participate in biobanks nor know-
ledge on biobanks. We are not discussing the motivations of Finns to participate or
not, but point out that it is questionable to talk about willingness if, rather than being
specifically asked for their consent, people’s information and samples are made avail-
able to biobanking by default – by using legislation as the basis for data and sample
collection. The article is motivated by concern about statements presented by biobank
proponents and innovation policy makers, and how the statements are employed in
strategies and argumentative communication related to promoting biobanking.
Data and analysis
Our argument is based on analysis of three types of data: 1) Finnish reports and strat-
egies related to biobanking from 2014 to 2016 (n = 5); 2) presentations and slideshows
promoting Finnish biobanking from 2013 to 2017 (n = 22); and 3) material collected
from the internet (including blogs, news and webpages) about biobanking from 2013 to
2018 (n = 15). The material has been gathered since 2013 for use in a range of research
projects in which the authors have been involved, which have dealt with biobanks and
biomedical infrastructures and policies (e.g., Snell et al. 2012, Tarkkala et al. 2018, Tarkkala
2019.). In these projects, we had noticed that the theme of a positive, trusting and willing
population was a prominent narrative in public discussion about biomedicine, the
biomedical R&D environment, science and biobanks. Wanting to examine it more
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thoroughly through the case of biobanking, we scanned a larger corpus of collected
material and picked the data set described above for closer analysis on the basis
that the texts used the narrative in question or referred to the Finnish population
and its role in biobanking in some way. We identified and classified different
manners of referring to the population and the terms and rhetorical tools that were
used in connection with it – such as willing population, the positive attitudes of patients,
trusting population, and tech-savvy Finns – and identified the contexts in which they were
deployed. The narrative of the willing population in particular offers insights into what it
promotes and legitimises. Thus we contribute to the discussions on policy and strategy
rhetoric around biomedicine and its social end ethical implications (Corrigan and Tutton
2006, Woolley et al. 2016, Tupasela 2011).
In addition, analysis reflects existing research on knowledge and opinions towards bio-
banking in Finland (Sihvo et al. 2007, Tupasela and Snell 2012, Snell 2017, Gaskell et al.
2013, Snell et al. 2012), as well as statistics of participation rates obtained by personally
requesting them from biobanks. Thus we do not analyse the motivations to participate as
such. Analysis is restricted to Finland, but the article raises important points which also
concern data-gathering and biobank initiatives elsewhere in terms of their socially sustain-
able development. Unpacking the premises and uses of rhetorical tools can make visible
taken-for granted assumptions that guide and legitimise policies and their implementation.
Positive, willing and engaged population
The rhetoric of a positive population has been utilized in public discussions of science
and technology, and had an especially important role at the strategic level and in
innovation policy documents in Finland throughout the 2000s (Snell 2009). In texts
related to biomedicine, biobanks and genomics, a ‘positive attitude’ is closely correlated
with willingness to participate in medical research and data repositories. In the Finnish
Genome Strategy (Ministry of Social Affairs and Health 2015), written to promote and
advance the usage and utilization of genomic data, it is said:
From a global perspective, Finland’s strengths include a high standard of healthcare,
uniform treatment practices, reliable healthcare registers, a long tradition of high-
quality genetic research, and the willingness of the population to participate in
scientific research. (Ministry of Social Affairs and Health 2015, 12.)
Similarly, the Health Sector Growth Strategy (The Ministry of Employment and the
Economy 2014, 33) states that “Finland also has patients who take a positive view of
studies, which significantly promotes clinical research activities.” And in a report evalu-
ating the integration of Finnish biobanks it is claimed that:
The potential and value proposition of biobanking efforts in Finland are unique due
a number of key attributes, including (i) the Finnish population’s exceptional genetic
founder characteristics, (ii) the depth, breadth, and decades-long track record of
Finnish Electronic Health Records (EHR) linked to a unique personal ID number,
(iii) the enactment of a progressive biobanking law, and (iv) the generally positive
attitude vis-à-vis participation in biomedical research of a highly educated populus.
(Ministry of Social Affairs and Health 2016, 5)
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This kind of rhetoric has been used in Finland for decades (see Snell 2009, Tupasela
2007, Tarkkala 2019.) to suggest, for example, that Finns have played a key role in stud-
ies on monogenetic diseases (see, e.g., Peltonen et al. 1999, 1920). Besides the afore-
mentioned strategy and policy documents, the positive and therefore willing population
also makes an appearance in material promoting Finnish biobanking and the potential
for biomedical research in Finland. One biobank touts Finland as an excellent location
for biobanking in its webpages in the following terms:
Compared to many other countries, Finland's prerequisites for creating valuable
biobanks are considered excellent. Finnish biobanks are supported by a uniform public
health system, precise registration of medical history, a population register and citizens
who have a positive attitude towards research work. (Auria Biobank 2013)
Sitra – an influential and independent fund reporting to Finnish parliament that is
commissioned with the task of probing the future and promoting qualitative and quantita-
tive economic growth – has prepared a slideshow entitled “Finland - Your testbed for re-
search and medical innovation” (Sitra 2015), which has been employed by many prominent
actors in the field of biobanking and biomedical research: biobank managers and professors
as well as representatives from ministries and companies. Due to their broad dissemination,
the slides can be considered highly influential promotional tools for Finland in the biomed-
ical research market, both at national and international events. One of the five reasons listed
in the slide sequence for why Finland is the most advanced testbed in the world, is its ‘en-
gaged population’, a small twist on the willing population narrative. An engaged population,
according to the Sitra slides, is constituted by four elements: high levels of education, a
marked willingness to participate, trust in the authorities and tech-savvy people. This raises
the question of how these elements foster engagement? Is trust in the authorities, for ex-
ample, the primary quality of an engaged population?
The positive and willing population also features in the Finland Health webpages to
promote the Finnish R&D environment in biomedicine and health technology. In one
article on its site, the Finnish consent rates to having samples stored are regarded as
‘astoundingly high’:
Finland boasts an astoundingly high consent rate when it comes to their rate of
consent: over 90% of Finns consent to donating their samples to a biobank upon
request! ... Finns rank at the top of the charts when it comes to trusting institutions and
valuing science. They understand the importance of science, and want to be involved in
furthering research. The positive Finnish attitude towards research is only one of the
reasons why Finland is the country for sample collecting. (FinlandHealth 2016)
Thus, high consent rates are accepted as a sign of positive attitudes; however, it is not
apparent what type of consent the site is talking about, because, while 90% may agree
‘upon request’, how many patients actually receive such a request? A similar ambiguity
is present in the abovementioned testbed slides that state that “95% of consent donators
have given consent of their samples [sic]” without specifying what samples, what do-
nors, and what consenting is in question. Firstly, it is difficult to construct a common
consent rate for biobanks, each of which has a different method for gaining consent
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and represents a range of general clinical, disease-specific and research-based biobanks,
while all are in different stages of operation: some have been collecting new samples
for years while others have more or less just started. Secondly, almost immediately after
the new biobanks began to collect new samples, it was noticed that receiving informed
consent from patients to do so was anything but simple and easy. The first clinical bio-
bank, for example, struggled to get a 25% return rate of informed consent forms.
Concern over consent rates – creating another use for the willing population
The legislative arrangements during the first years of establishing biobanks form one
background for the connection between the rhetoric of success and high consent rates.
The Biobank Act provides Finnish biobanks with two routes to acquiring biological
samples: integrating existing collections or collecting new prospective samples. These
procurement methods entail different practices in terms of consent. Old research, clin-
ical or diagnostic collections could be transferred to a new biobank within a certain
timeframe merely by following a notification procedure – an advertisement in a news-
paper has been considered sufficient (Soini 2016). The sample ‘donor’ can then opt out
of the biobank if so desired. In contrast, new samples require informed and written
consent. While there have been hardly any opt-outs from the old collections, nowadays
referred as ‘legacy samples’, this cannot be regarded as willingness to participate. It is
likely that many past donors have not seen the ads in the newspapers, and do not know
that their old clinical and diagnostic samples have been transferred to a biobank; nor,
possibly, do they know about their right to opt out. Furthermore, as mentioned above,
most Finns do not know what biobanks are. Recent survey results show that only 40%
of Finns have heard of them and, of those, 63% are considered to have insufficient
understanding of them to make an informed decision (Snell 2017). Being a willing
participant in a biobank requires, first of all, knowledge about their existence and,
secondly, awareness of the possibility that one’s samples and related data can be stored
in one. Incidentally, to put the legacy samples in context, it was estimated that over
two million Finns would become participants in biobanks due to the transfer of old
samples (Sosiaali- ja terveysministeriö 2007, 20), and millions of samples have since
been transferred. Meanwhile, by the end of 2017, only about 126,000 informed consents
had been acquired for prospective sampling (Biopankki.fi 2017).
Currently, the findings in surveys or qualitative studies of favourable attitudes to-
wards medical research do not translate in a straightforward manner into high consent
rates or participation in biobanks. Even though research shows consistently positive
attitudes towards science and medicine in Finland, people either remain unaware of
what biobanking is or they hold preconceptions and concerns about biobanking and
medical research that require attention (Tupasela and Snell 2012). While research
shows that educated citizens in particular have positive attitudes, it is also they who
understand that there is a wider context of biobank research that needs to be addressed
(Snell 2017). This is reflected in their concerns about the consequences of biobanking
in society, and the issues of control, equality, transparency and commercialisation
related to the storage and circulation of biobank information; these appear to be their
main worries along with a general unease about the unknown future of biobanking
(Snell et al. 2012, Tupasela and Snell 2012, Critchley et al. 2015, Meskus 2018).
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As stated, gathering new, prospective samples or integrating new information and old
samples requires informed consent from the donors. The consent rate has been disap-
pointing for many hospital biobanks (Heino 2016). The early enthusiasm and rhetoric
about a willing population that participates in biobanks rather swiftly attracted a simultan-
eous concern with consent rates; consequently, the consent process was framed as the
problem hindering and slowing down the actualization of success in the field. Mentioned
above, this was clearly stated in a report discussing the integration of Finnish biobanks:
An important current bottleneck is sample collection, which is hampered by the
current informed consenting processes that have turned out to be less than optimally
effective. (Ministry of Social Affairs and Health 2016, 9).
According to our biobank informants, only 20%–50% of the consent forms for new
samples sent by mail to potential donors had been returned to the biobanks, although
only a very small minority of the returned forms had been refusals. Thus people
seemed unprepared to take a stand. Quantitative findings support this as one survey
found 44% of respondents were interested in giving their samples to a biobank while
45% were uncertain (Snell 2017). Some biobanks have invested in ‘biobank ambassa-
dors’, who tour hospital clinics to collect informed consent documents in person. This
method has proved more successful numerically and Helsinki Biobank, for example,
has reached its targets. This type of recruitment is, however, regarded as time and
money consuming and therefore inefficient.
The National Institute of Health and Wellbeing (THL) has had a higher success rate
in acquiring informed consent, as it recruits people to take part in health research pro-
jects and to the THL biobank. But their consent rate is based on people who have
already decided to participate in a research project, after which it might be easier to
accept biobank participation. Meanwhile, there has also been considerable discussion
and concern about declining participation rates in epidemiological and clinical research
projects (Mindell et al., 2015).
The report on the integration of biobanks that identified the bottleneck continues by
providing another rhetorical use of the willing population, observing that if people are
in general positive, seeking informed consent might not be the way forward. The report
refers to planned legislation regarding the secondary use of health data.
Since a great majority of Finns is willing to provide biobank consent and samples, we
need new ideas and resources to address this critical bottleneck. The planned change in
legislation regarding a liberalization of the secondary use of data is one important step in
the right direction in this regard. (Ministry of Social Affairs and Health 2016, 9)
The idea of the legislation is that all health data should be considered as register
information gathered on legislative grounds and therefore an opt-out mechanism is
preferable to informed consent. In a blog text from 2016 a prominent Finnish professor
drew attention to the educated sector of the population and patients who want to
participate in biobanks but have difficulties because of the highly bureaucratic consent
process, suggesting that this is hindering biobank development in Finland. He also sug-
gests the opt-out procedure as an attractive alternative to informed consent:
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The solution most worthy of support would be, that by default, when a patient
enters public health care, along with taking another blood sample a biobank sample
would be taken, unless he specifically declines it. (Palotie, 2016)
Thus, despite the consent ‘bottleneck’, the positive population is still seen as one of
the key strengths of prospective biobanking in Finland, with its ‘willingness’ serving as
evidence that informed consent is actually not needed. Even the report identifying the
bottleneck mentions the positive population as a key attribute of value creation for bio-
banks (Ministry of Social Affairs and Health 2016, 5). It is thus being proposed that the
trope of the willing population be used to enable the dismantling of informed consent
procedures based on the population’s extrapolated readiness to participate; this is
regarded as the solution to the acknowledged difficulty in recruiting participants.
Johnsson et al. (2010, 1261) have suggested that the “willingness to participate in
research” expressed in surveys “may not always predict actual participation rates” and
thus, “the value of surveys in assessing factual willingness may thus be limited”. They
add that this is why actual participation rates are higher than surveys indicate, because
of factors present in face-to-face situations. Our analysis does not fully support these
findings, however, as the actual consent rates were lower than expected. Van Zon et al.
(2016) also mention lower actual participation rates in many biobank studies, arguing
that people might be more prone to give a socially desirable answer to a hypothetical
study costing the hypothetical participants no time or effort. We agree with Van Zon et
al.’s assessment that hypothetical situations do not reflect real situations where people
have to make concrete and possibly long-lasting decisions based on inadequate know-
ledge. Yet we also agree with Johnsson et al. that personal encounters increase partici-
pation rates, as has become evident in the recruiting procedures of some biobanks and
clinics. Biobank ambassadors have been successful in face-to-face recruiting and con-
sent forms acquired in disease-specific biobanks where the consent process is more
personal have been high. One biobank manager describes the success of face-to-face
recruiting as follows:
Consent is currently 98%. Most people from whom consent has been asked, have
given it. Biobank operations have been received very positively… People want to be
part of developing Finnish medicine. (HUS 2016)
The number of people formally consenting is indeed on the rise, from 3000 in 2014
to over 120,000 at the end of 2017 (Biopankki.fi 2017). The instigation of new biobanks
as well as some large research projects that include biobank consent have contributed
to these figures.
Discussion
We do not question the positive attitudes towards science and medicine expressed by
Finns and demonstrated in numerous surveys and research articles. We also acknowledge
that the rising number of informed consents is an indicator of increasing familiarity with
biobanking, as well as growing efforts and resources allocated to the recruitment of
biobank participants. Thus, our aim is not to claim that people will not participate in
biobanking in the long run. Instead, we have directed our critical gaze at the rhetoric that
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uses the idea of a positive and trusting population in a manner that we do not consider
socially or ethically robust. Critical social analysis has to go beyond these kinds of estab-
lished narratives and taken-for-granted assumptions that continue to circulate around
biomedicine.
We approached out case from two viewpoints. First, we underlined how research on
public opinion has consistently demonstrated that biobanking has been, and still is, an
alien concept for Finns (Sihvo et al. 2007, Snell 2017). Despite this, the rhetoric of a
willing and engaged population continues to be deployed; indeed, it even appeared in
the early phases of Finnish biobanks when there was no evidence either way about con-
sent rates. Second, we were concerned by how the argumentation of a willing and en-
gaged population is being used as evidence to circumvent the consent process in favour
of an opt-out model.
Supporting and positive attitudes or high levels of general trust in a given society are
not in themselves straightforward indications of people’s actual willingness and prepared-
ness to participate in biobanking. During the first years of biobank sample collecting in
Finland, it was acknowledged that attaining informed consent from patients and citizens
was creating a bottleneck and thus the consent procedure came to be regarded as hinder-
ing the development of biobanking and biomedicine. Even though the low participation
rate was seen as a challenge, the actors and proponents of biobanking framed it as a prac-
tical issue, suggesting that the consent process was of the wrong kind. The actual support
and willingness of people to participate was not put under scrutiny.
Simultaneously, the informed consent previously seen as a prerequisite for respon-
sible and transparent biobanking practices seemed to lose its significance. We suggest
that it is not valid to portray the consent process as unnecessary simply because people
do not act as was expected and hoped of them (see also Sterckx et al. 2016). It might
be meaningful to consider whether this situation and reasoning is indicative of what
happens as innovation policy increasingly becomes a key framing of personalized medi-
cine initiatives (see Tarkkala et al. 2018). As the willing population continues to figure
in different strategy materials related to biobanking, personalised medicine and health
sector innovations, it would be wise to investigate the grounds on which a population
may be regarded as ‘willing’ in the first place. We acknowledge that an opt-out system
has advantages - it is a more efficient way to collect samples and data and can also be
preferred by biobank participants. We have not aimed to take a stance for or against
informed consent or opt-out as such, but want to highlight how certain rhetoric is
embraced to drive certain and sometimes changing ends. In our case, the rhetoric of
willing population is utilised not to convince public to support biobanks but to
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